Navigation Links
Aerolase Retains SMH Capital Inc. to Advise on Corporate Expansion
Date:9/19/2008

NEW YORK, Sept. 19 /PRNewswire/ -- Aerolase, the manufacturer of medical aesthetic lasers, announced today that it has retained SMH Capital Inc., a subsidiary of Sanders Morris Harris Group (Nasdaq: SMHG), as its financial advisor to explore financing alternatives to fund expansion into new markets.

The additional funding will be primarily directed toward expanding the Aerolase sales channel expansion into the market of about 300,000 U.S. primary care practitioners. This physician group is actively adding medical aesthetics to their practices to serve continuing strong demand for cosmetic-rejuvenation procedures, especially from affluent baby boomers.

"This is a unique opportunity for Aerolase," said CEO Dr. Pavel Efremkin. "Many physicians are now starting their new medical aesthetic practice, and YAG laser device is a "must-have" or "first-to-buy" laser for any medical aesthetic practitioner. Our LightPod Neo, because of its unique versatility, pain-free performance and portability, is undeniably the best YAG laser for this new market. With the expansion funding we will make LightPod the best selling medical laser on the market."

"We see tremendous potential for dramatic growth as medical aesthetic practitioners learn about the benefits of the LightPod Neo," said Mitchell Stern, Managing Director of SMH Capital Inc. "Aerolase is poised to capture a significant share of the aesthetic laser market over the next six to 12 months with sufficient funds to support expansion."

About Aerolase

Aerolase Corporation, Tarrytown, NY, is a world leader in the miniaturization of high-powered medical lasers. This core technology has been commercialized in the fields of medical & aesthetic dermatology as well as capillary blood testing and diabetes management.

The company's LightPod(R) lasers cover most aesthetic laser procedures on all skin types as well as many medical treatments. Aerolase lasers are packaged in the innovative LightPod system which utilizes air, rather than water, to continuously cool the internal laser emitter; this patented breakthrough resulted in a laser system that is portable and maintenance-free, also inherently less costly to manufacture and therefore more affordable. For more information, visit http://www.aerolase.com.

About Sanders Morris Harris Group

Sanders Morris Harris Group is a financial services company that manages $11 billion in client assets. It has two primary businesses. Asset/Wealth Management, the largest, provides highly regarded wealth advisory and asset management services to individuals and institutions. The other, Capital Markets, offers investment banking, institutional brokerage, trading, and research to a variety of institutions and middle market companies. Its corporate philosophy of investment in common aligns its interests with those of its clients. Sanders Morris Harris has over 600 employees in 21 states. Additional information is available at http://www.smhgroup.com.


'/>"/>
SOURCE Aerolase
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
2. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
3. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
4. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
5. Dragon retains leading investor relations firm
6. Interleukin Genetics Retains Top Life Science Communications Firms
7. SPO Medical Retains American Capital Ventures for Investor Relations Services
8. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
9. CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing
10. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
11. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
(Date:1/19/2017)... , ... January 19, 2017 ... ... advanced software solutions for pharmaceutical research and development (R&D), today announced the ... omic data analysis and interpretation for the rapidly evolving field of precision ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... 2017 AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: ... aquaculture and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... the listing of its common shares on the NASDAQ ... "AquaBounty,s listing on NASDAQ represents an important ... to the U.S. markets as we advance plans for ...
Breaking Biology Technology:
(Date:1/6/2017)... Calif. , Jan. 5, 2017  Delta ID ... its iris scanning technology for automotive at CES® 2017. ... GNTX ) to demonstrate the use of iris ... identify and authenticate the driver in a car, and ... during the driving experience. Delta ID and ...
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
Breaking Biology News(10 mins):